中华消化内镜杂志
中華消化內鏡雜誌
중화소화내경잡지
CHINESE JOURNAL OF DIGESTIVE ENDOSCOPY
2013年
9期
515-518
,共4页
周光平%智发朝%张亚历%肖冰%巩兰波%李明松%张振书%陈村龙%白杨
週光平%智髮朝%張亞歷%肖冰%鞏蘭波%李明鬆%張振書%陳村龍%白楊
주광평%지발조%장아력%초빙%공란파%리명송%장진서%진촌룡%백양
结肠炎,溃疡性%药物疗法%英夫利昔%临床表现%黏膜愈合%不良反应
結腸炎,潰瘍性%藥物療法%英伕利昔%臨床錶現%黏膜愈閤%不良反應
결장염,궤양성%약물요법%영부리석%림상표현%점막유합%불량반응
Colitis,ulcerative%Drug therapy%Infliximab%Clinical manifestations%Mucosal healing%Adverse reactions
目的 评价英夫利昔治疗溃疡性结肠炎的疗效.方法 收集38例行糖皮质激素+美沙拉秦治疗和(或)英夫利昔治疗的中重度活动期溃疡性结肠炎患者的病例资料,其中35例行糖皮质激素+美沙拉秦治疗者纳入对照组,13例行糖皮质激素+美沙拉秦治疗后黏膜未愈合接受英夫利昔治疗者及3例直接行英夫利昔治疗者纳入观察组.提取临床资料并进行随访,分析临床有效率、内镜下黏膜愈合率、复发情况、不良反应情况及实验室检查指标变化.结果 对照组有效21例(60.0％),其中缓解8例(22.9％,8/35),内镜下黏膜愈合8例(22.9％)；观察组有效15例(93.8％),其中缓解9例(56.3％,9/16),内镜下黏膜愈合9例(56.3％).观察组的临床有效率、缓解率、内镜下黏膜愈合率均明显高于对照组,差异均有统计学意义(P＜0.05).英夫利昔治疗后血沉、C反应蛋白较治疗前明显降低,差异均有统计学意义(P＜0.05)；对于肠外表现及并发症,部分有效；3例出现轻微不良反应；随访过程中有3例仍维持缓解,有4例复发.结论 英夫利昔治疗中重度活动期溃疡性结肠炎疗效确切,能缓解临床症状,还可使部分达到黏膜愈合,且无严重不良反应,但仍有部分缓解后复发.
目的 評價英伕利昔治療潰瘍性結腸炎的療效.方法 收集38例行糖皮質激素+美沙拉秦治療和(或)英伕利昔治療的中重度活動期潰瘍性結腸炎患者的病例資料,其中35例行糖皮質激素+美沙拉秦治療者納入對照組,13例行糖皮質激素+美沙拉秦治療後黏膜未愈閤接受英伕利昔治療者及3例直接行英伕利昔治療者納入觀察組.提取臨床資料併進行隨訪,分析臨床有效率、內鏡下黏膜愈閤率、複髮情況、不良反應情況及實驗室檢查指標變化.結果 對照組有效21例(60.0％),其中緩解8例(22.9％,8/35),內鏡下黏膜愈閤8例(22.9％)；觀察組有效15例(93.8％),其中緩解9例(56.3％,9/16),內鏡下黏膜愈閤9例(56.3％).觀察組的臨床有效率、緩解率、內鏡下黏膜愈閤率均明顯高于對照組,差異均有統計學意義(P＜0.05).英伕利昔治療後血沉、C反應蛋白較治療前明顯降低,差異均有統計學意義(P＜0.05)；對于腸外錶現及併髮癥,部分有效；3例齣現輕微不良反應；隨訪過程中有3例仍維持緩解,有4例複髮.結論 英伕利昔治療中重度活動期潰瘍性結腸炎療效確切,能緩解臨床癥狀,還可使部分達到黏膜愈閤,且無嚴重不良反應,但仍有部分緩解後複髮.
목적 평개영부리석치료궤양성결장염적료효.방법 수집38례행당피질격소+미사랍진치료화(혹)영부리석치료적중중도활동기궤양성결장염환자적병례자료,기중35례행당피질격소+미사랍진치료자납입대조조,13례행당피질격소+미사랍진치료후점막미유합접수영부리석치료자급3례직접행영부리석치료자납입관찰조.제취림상자료병진행수방,분석림상유효솔、내경하점막유합솔、복발정황、불량반응정황급실험실검사지표변화.결과 대조조유효21례(60.0％),기중완해8례(22.9％,8/35),내경하점막유합8례(22.9％)；관찰조유효15례(93.8％),기중완해9례(56.3％,9/16),내경하점막유합9례(56.3％).관찰조적림상유효솔、완해솔、내경하점막유합솔균명현고우대조조,차이균유통계학의의(P＜0.05).영부리석치료후혈침、C반응단백교치료전명현강저,차이균유통계학의의(P＜0.05)；대우장외표현급병발증,부분유효；3례출현경미불량반응；수방과정중유3례잉유지완해,유4례복발.결론 영부리석치료중중도활동기궤양성결장염료효학절,능완해림상증상,환가사부분체도점막유합,차무엄중불량반응,단잉유부분완해후복발.
Objective To investigate the effects with infliximab to treat ulcerative colitis.Methods Selected 38 cases treated with glucosteroid + mesalazine and (or) infliximab of active moderate to severe ulcerative colitis,chose 35 patients with active moderate to severe ulcerative colitis treated with glucosteroid + mesalazine as a control group,13 patients treated with infliximab after no mucosal healing from glucosteroid + mesalazine and the 3 patients who treated directly with infliximab as a observe group.Extracted all clinical data and follow-up,then analysed clinical effective rate,mucosal healing rate,recurrence,adverse reactions and laboratory results changes.Results Twenty-one cases in control group (60％) were effective,remission 8 cases (22.9％,8/35),mucosal healing 8 cases (22.9％).Fifteen cases in observe group (93.8％) were effective,remission 9 cases (56.3％,9/16),and mucosal healing 9 cases (56.3％).The clinical effective rate,remission rate,mucosal healing rate in observe group were significandy higher than in the control group (P ＜0.05).The ESR and CRP decreased obviously after treated with infliximab with statistical significance (P ＜ 0.05).Parenteral manifestations and complications were partially cured.Three cases with mild adverse reactions.Follow-up of 3 cases remained remission,4 cases recurrence.Condusion Infliximab has certain effects on active moderate to severe ulcerative colitis,which can alleviate clinical symptom.Some patients could achieve mucosal healing,and no serious adverse reactions happened.But still some patients relapsed after remission.
